Pms38 - Cost Effectiveness Analysis of Secukinumab Versus Ustekinumab for the Treatment of Psoriatic Arthritis in the United States
Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.1752
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV